A Phase 3 interventional study of liraglutide and placebo in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 82 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-11-17.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 151 studies testing liraglutide in Diabetes Mellitus, Type 2 — 6 open to participants now, 7 under way, 1 of them phase 3. Liraglutide · Diabetes Mellitus, Type 2.
Among the 151 studies testing liraglutide in Diabetes Mellitus, Type 2, this one is the 34th largest by enrollment, is one of 6 that started in 2017, is one of 45 in phase 3, and was the 125th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →6 of the 151 studies testing liraglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 25–70
Mansa · Sites in United States
Ages 10+
Biolingus · Sites in Hong Kong
Ages 18–65
RenJi Hospital · Sites in China
Ages 18–65
University of Virginia · Sites in United States
Ages 21–60 · Healthy volunteers
By country, each count listing its studies:
Liraglutide: first FDA approval 2010 (VICTOZA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
151 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 27 · Phase 2 21 · Phase 3 46 · Phase 4 48
First in 1999; this study’s year is marked. 6 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 303 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 62 across the 151 interventional studies. Of the 127 that completed or were terminated, 52 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
75 of 151 have an industry lead sponsor. The 10 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,410 studies on the registry; 107 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
644 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S: 26 open now, 30 under way, 11 of them phase 3. Of 603 finished, 174 (29%) have results posted.
Among the 644 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S, this one is the 166th largest by enrollment of the 429 interventional ones that give a count, is one of 17 that started in 2017, is one of 187 in phase 3, and was the 427th registered.
Novo Nordisk A/S’s Diabetes Mellitus, Type 2 studies by the year they started, since 1997.
1 of the studies testing liraglutide in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03883412University of VirginiaEffect of Exercise and/or Liraglutide on Vascular Dysfunction and Insulin Sensitivity in Type 2 Diabetes ( ZQL007) | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 151 studies testing liraglutide in Diabetes Mellitus, Type 2, from their registry updates:
Among Novo Nordisk A/S’s 644 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
The trial is conducted in Asia, Europe, North America and South America. The aim of the study is to compare the effect of liraglutide 1.8 mg/day versus placebo as add-on to an SGLT2 inhibitor with or without metformin on glycaemic control in subjects with type 2 diabetes mellitus.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
This study's enrollment of 303 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Browse Diabetes Mellitus, Type 2 studies →Novo Nordisk A/S is the lead sponsor of 1,410 studies on the registry; 107 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: liraglutide
Drug: placebo
Liraglutide given s.c. once daily, gradually titrated to 1.8 mg/day as an add-on to the subject's stable pre-trial SGLT2 inhibitor ± metformin for 26 weeks
Liraglutide placebo given s.c. once daily, gradually titrated to 1.8 mg/day as an add-on to the subject's stable pre-trial SGLT2 inhibitor ± metformin for 26 weeks
Change in HbA1c
Change from baseline (week 0) to week 26 in glycosylated haemoglobin was evaluated for 2 different observation period 'in-trial' observation period and 'on-treatment without rescue medication" observation period. The 'in-trial' observation period represents the time-period where subjects were considered to be in the trial, regardless of whether or not the subjects had initiated rescue medication or prematurely discontinued trial product. The 'on-treatment' observation period is the part of the in-trial observation period during which subjects were treated with the trial product, that is the time from the first dose to the last dose of trial product. The 'on-treatment without rescue medication' observation period is a part of 'on-treatment' observation period during which subjects were considered treated with trial product and had not initiated any rescue medications.
Time frame: Week 0, Week 26
Change in Body Weight
Change from baseline (week 0) to week 26 in body weight was evaluated for 2 different observation period 'in-trial' observation period and 'on-treatment without rescue medication" observation period. The 'in-trial' observation period represents the time-period where subjects were considered to be in the trial, regardless of whether or not the subjects had initiated rescue medication or prematurely discontinued trial product. The 'on-treatment' observation period is the part of the in-trial observation period during which subjects were treated with the trial product, that is the time from the first dose to the last dose of trial product. The 'on-treatment without rescue medication' observation period is a part of 'on-treatment' observation period during which subjects were considered treated with trial product and had not initiated any rescue medications.
Time frame: Week 0, Week 26
Change in Fasting Plasma Glucose
Change from baseline (week 0) to week 26 in fasting plasma glucose ('in-trial' observation period)
Time frame: Week 0, Week 26
Subjects Who Achieve HbA1c Below 7.0% (53 mmol/Mol), American Diabetes Association Target
Percentage of subjects who achieve HbA1c below 7.0% (53 mmol/mol), American Diabetes Association target, after 26 weeks ('in-trial' observation period)
Time frame: Week 26
Subjects Who Achieve HbA1c Below or Equal to 6.5% (48 mmol/Mol), American Association of Clinical Endocrinologists Target
Percentage of subjects who achieve HbA1c below or equal to 6.5% (48 mmol/mol), American Association of Clinical Endocrinologists target, after 26 weeks ('in-trial' observation period)
Time frame: Week 26
Subjects Who Achieve HbA1c Below 7.0% (53 mmol/Mol) Without Severe or Blood Glucose Confirmed Symptomatic Hypoglycaemia Episodes and no Weight Gain.
Percentage of subjects who achieve HbA1c below 7.0% (53 mmol/mol) without severe or blood glucose confirmed symptomatic hypoglycaemia episodes and no weight gain, after 26 weeks ('in-trial' observation period)
Time frame: Week 26
Subjects Who Achieve HbA1c Reduction Above or Equal to 1% (11mmol/Mol) and Weight Loss Above or Equal to 3%.
Percentage of subjects who achieve HbA1c reduction above or equal to 1% (11mmol/mol) and weight loss above or equal to 3%, after 26 weeks ('in-trial' observation period)
Time frame: Week 26
Change in Self-measured Plasma Glucose 7-point Profile - Mean 7-point Profile
Change in self-measured plasma glucose 7-point profile - mean 7-point profile after 26 weeks. Subjects were instructed to measure their plasma glucose at following 7 timepoints: before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after start of dinner, at bedtime. Mean of the 7-point profile was calculated ('in-trial' observation period).
Time frame: Week 0, Week 26
Change in Self-measured Plasma Glucose 7-point Profile - Mean Post Prandial Increments (Over All Meals)
Subjects were instructed to measure their plasma glucose at following 7 timepoints: before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after start of dinner, at bedtime. The mean increment over all meals was derived as the mean of all available meal increments ('in-trial' observation period)
Time frame: Week 0, Week 26
Change in Body Mass Index (BMI)
Observed mean change from baseline (week 0) to week 26 in body mass index (BMI). BMI was calculated based on body weight and height ('in-trial' observation period)
Time frame: Week 0, Week 26
Subjects Who Achieve HbA1c Below 7.0% (53 mmol/Mol) and no Weight Gain
Percentage of subjects who achieve HbA1c below 7.0% (53 mmol/mol) and no weight gain, after 26 week ('in-trial' observation period).
Time frame: Week 26
Subjects Who Achieve HbA1c Below 7.0% (53 mmol/Mol), no Weight Gain and Systolic Blood Pressure Below 140 mmHg.
Percentage of subjects who achieve HbA1c below 7.0% (53 mmol/mol), no weight gain and systolic blood pressure below 140 mmHg, after 26 weeks ('in-trial' observation period)
Time frame: Week 26
Subjects Who Achieve HbA1c Reduction Above or Equal to 1% (11mmol/Mol)
Percentage of subjects who achieve HbA1c reduction above or equal to 1% (11mmol/mol), after 26 weeks ('in-trial' observation period)
Time frame: Week 26
Subjects Who Achieve HbA1c Reduction Above or Equal to 1% (11mmol/Mol) and no Weight Gain
Percentage of subjects who achieve HbA1c reduction above or equal to 1% (11mmol/mol) and no weight gain, after 26 weeks.
Time frame: Week 26
Number of Treatment Emergent Adverse Events
The on-treatment summary of adverse events includes treatment-emergent events with onset on or after the first day of exposure to randomised treatment and no later than the minimum of the date of the follow-up visit or the last day of randomised treatment + 7 days or the date of last subject-investigator contact.
Time frame: Week 0 - 26 + 7 days
Number of Treatment Emergent Severe or Blood Glucose Confirmed Symptomatic Hypoglycaemia Episodes
Treatment emergent hypoglycaemic episode is defined episode with onset on or after the first day of exposure to randomised treatment and no later than the minimum of the date of the follow-up visit or the last day of randomised treatment + 1 days or the date of last subject-investigator contact. Severe or BG confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe according to American Diabetes Association's (ADA) classification or blood glucose confirmed by a plasma glucose value \< 3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. Severe hypoglycaemia according to the ADA definition: an episode requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions.
Time frame: Week 0 - 26
Change in Fasting Blood Lipids - Total Cholesterol
Fasting total cholesterol measured in mg/dL. Observed mean change in fasting total cholesterol from baseline (week 0) to week 26 is presented as ratio to baseline value.
Time frame: Week 0, Week 26
Change in Fasting Blood Lipids - Low Density Lipoprotein (LDL) Cholesterol
Low density lipoprotein (LDL) cholesterol measured in mg/dL. Observed mean change in fasting low density lipoprotein cholesterol from baseline (week 0) to week 26 is presented as ratio to baseline value.
Time frame: Week 0, Week 26
Change in Fasting Blood Lipids - High Density Lipoprotein (HDL) Cholesterol
High density lipoprotein (HDL) cholesterol measured in mg/dL. Observed mean change in fasting high density lipoprotein cholesterol from baseline (week 0) to week 26 is presented as ratio to baseline value.
Time frame: Week 0, Week 26
Change in Fasting Blood Lipids - Very Low Density Lipoprotein (VLDL) Cholesterol
Very low density lipoprotein (VLDL) cholesterol measured in mg/dL. Observed mean change in fasting very low density lipoprotein cholesterol from baseline (week 0) to week 26 is presented as ratio to baseline value.
Time frame: Week 0, Week 26
Change in Fasting Blood Lipids-triglycerides
Fasting triglycerides measured in mg/dL. Observed mean change in fasting triglycerides from baseline (week 0) to week 26 is presented as ratio to baseline value.
Time frame: Week 0, Week 26
Change in Fasting Blood Lipids- Free Fatty Acids (FFA)
Free fatty acids measured in mg/dL. Observed mean change in fasting free fatty acids from baseline (week 0) to week 26 is presented as ratio to baseline value.
Time frame: Week 0, Week 26
Change in Waist Circumference
Change from baseline (week 0) to week 26 in waist circumference ('in-trial' observation period).
Time frame: Week 0, Week 26
Change in Systolic Blood Pressure
Change from baseline (week 0) in systolic blood pressure after 26 weeks ('in-trial' observation period).
Time frame: Week 0, Week 26
Change in Diastolic Blood Pressure
Change from baseline (week 0) in diastolic blood pressure after 26 weeks ('in-trial' observation period).
Time frame: Week 0, Week 26
Subjects Who Achieve Weight Loss by 3% or More
Percentage of subjects who achieve HbA1c reduction above or equal to 1% (11mmol/mol) and weight loss above or equal to 3%, after 26 weeks ('in-trial' observation period).
Time frame: Week 26
The trial was conducted at 74 sites in 7 countries. All the sites have screened and randomised subjects. Brazil: 3 sites, India: 7 sites, Israel: 6 sites, Mexico: 2 sites, Russian Federation: 3 sites, United Arab Emirates: 5 sites, United States: 48 sites screened and randomised subjects.
| Milestone | Liraglutide | Placebo |
|---|---|---|
| Started | 203 | 100 |
| Exposed to trial product | 202 | 100 |
| Completed | 200 | 98 |
| Not completed | 3 | 2 |
| Withdrew: Lost to follow-up | 2 | 0 |
| Withdrew: Withdrawal by subject | 1 | 2 |
Change from baseline (week 0) to week 26 in glycosylated haemoglobin was evaluated for 2 different observation period 'in-trial' observation period and 'on-treatment without rescue medication" observation period. The 'in-trial' observation period represents the time-period where subjects were considered to be in the trial, regardless of whether or not the subjects had initiated rescue medication or prematurely discontinued trial product. The 'on-treatment' observation period is the part of the in-trial observation period during which subjects were treated with the trial product, that is the time from the first dose to the last dose of trial product. The 'on-treatment without rescue medication' observation period is a part of 'on-treatment' observation period during which subjects were considered treated with trial product and had not initiated any rescue medications.
| Percentage of HbA1c | Liraglutide | Placebo |
|---|---|---|
| in-trial obs. period | -1.00 ± 0.86 | -0.32 ± 0.83 |
| on-treatment without rescue medication obs. period | -1.05 ± 0.85 | -0.35 ± 0.80 |
Change from baseline (week 0) to week 26 in body weight was evaluated for 2 different observation period 'in-trial' observation period and 'on-treatment without rescue medication" observation period. The 'in-trial' observation period represents the time-period where subjects were considered to be in the trial, regardless of whether or not the subjects had initiated rescue medication or prematurely discontinued trial product. The 'on-treatment' observation period is the part of the in-trial observation period during which subjects were treated with the trial product, that is the time from the first dose to the last dose of trial product. The 'on-treatment without rescue medication' observation period is a part of 'on-treatment' observation period during which subjects were considered treated with trial product and had not initiated any rescue medications.
| Kg | Liraglutide | Placebo |
|---|---|---|
| in-trial obs. period | -2.84 ± 3.83 | -2.02 ± 3.32 |
| on-treatment without rescue medication obs. period | -2.89 ± 3.81 | -2.09 ± 2.96 |
Change from baseline (week 0) to week 26 in fasting plasma glucose ('in-trial' observation period)
| milligram/dL | Liraglutide | Placebo |
|---|---|---|
| Change in Fasting Plasma Glucose | -27.00 ± 35.01 | -11.97 ± 45.20 |
Percentage of subjects who achieve HbA1c below 7.0% (53 mmol/mol), American Diabetes Association target, after 26 weeks ('in-trial' observation period)
| Percentage of Participants | Liraglutide | Placebo |
|---|---|---|
| Yes | 51.79 | 23.16 |
| No | 48.21 | 76.84 |
Percentage of subjects who achieve HbA1c below or equal to 6.5% (48 mmol/mol), American Association of Clinical Endocrinologists target, after 26 weeks ('in-trial' observation period)
| Percentage of Participants | Liraglutide | Placebo |
|---|---|---|
| Yes | 34.36 | 9.47 |
| No | 65.64 | 90.53 |
Percentage of subjects who achieve HbA1c below 7.0% (53 mmol/mol) without severe or blood glucose confirmed symptomatic hypoglycaemia episodes and no weight gain, after 26 weeks ('in-trial' observation period)
| Percentage of Participants | Liraglutide | Placebo |
|---|---|---|
| Yes | 47.69 | 19.15 |
| No | 52.31 | 80.85 |
Percentage of subjects who achieve HbA1c reduction above or equal to 1% (11mmol/mol) and weight loss above or equal to 3%, after 26 weeks ('in-trial' observation period)
| Percentage of Participants | Liraglutide | Placebo |
|---|---|---|
| Yes | 29.74 | 7.45 |
| No | 70.26 | 92.55 |
Change in self-measured plasma glucose 7-point profile - mean 7-point profile after 26 weeks. Subjects were instructed to measure their plasma glucose at following 7 timepoints: before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after start of dinner, at bedtime. Mean of the 7-point profile was calculated ('in-trial' observation period).
| milligram/dL | Liraglutide | Placebo |
|---|---|---|
| Change in Self-measured Plasma Glucose 7-point Profile - Mean 7-point Profile | -33.93 ± 37.17 | -18.85 ± 40.81 |
Subjects were instructed to measure their plasma glucose at following 7 timepoints: before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after start of dinner, at bedtime. The mean increment over all meals was derived as the mean of all available meal increments ('in-trial' observation period)
| milligram/dL | Liraglutide | Placebo |
|---|---|---|
| Change in Self-measured Plasma Glucose 7-point Profile - Mean Post Prandial Increments (Over All Meals) | -11.06 ± 41.29 | -4.44 ± 44.77 |
Observed mean change from baseline (week 0) to week 26 in body mass index (BMI). BMI was calculated based on body weight and height ('in-trial' observation period)
| kg/m^2 | Liraglutide | Placebo |
|---|---|---|
| Change in Body Mass Index (BMI) | -1.02 ± 1.40 | -0.72 ± 1.20 |
Percentage of subjects who achieve HbA1c below 7.0% (53 mmol/mol) and no weight gain, after 26 week ('in-trial' observation period).
| Percentage of Participants | Liraglutide | Placebo |
|---|---|---|
| Yes | 47.69 | 19.15 |
| No | 52.31 | 80.85 |
Percentage of subjects who achieve HbA1c below 7.0% (53 mmol/mol), no weight gain and systolic blood pressure below 140 mmHg, after 26 weeks ('in-trial' observation period)
| Percentage of Participants | Liraglutide | Placebo |
|---|---|---|
| Yes | 42.05 | 18.09 |
| No | 57.95 | 81.91 |
Percentage of subjects who achieve HbA1c reduction above or equal to 1% (11mmol/mol), after 26 weeks ('in-trial' observation period)
| Percentage of Participants | Liraglutide | Placebo |
|---|---|---|
| Yes | 52.31 | 16.84 |
| No | 47.69 | 83.16 |
Percentage of subjects who achieve HbA1c reduction above or equal to 1% (11mmol/mol) and no weight gain, after 26 weeks.
| Percentage of Participants | Liraglutide | Placebo |
|---|---|---|
| Yes | 45.13 | 14.89 |
| No | 54.87 | 85.11 |
The on-treatment summary of adverse events includes treatment-emergent events with onset on or after the first day of exposure to randomised treatment and no later than the minimum of the date of the follow-up visit or the last day of randomised treatment + 7 days or the date of last subject-investigator contact.
| Events | Liraglutide | Placebo |
|---|---|---|
| Number of Treatment Emergent Adverse Events | 426 | 106 |
Treatment emergent hypoglycaemic episode is defined episode with onset on or after the first day of exposure to randomised treatment and no later than the minimum of the date of the follow-up visit or the last day of randomised treatment + 1 days or the date of last subject-investigator contact. Severe or BG confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe according to American Diabetes Association's (ADA) classification or blood glucose confirmed by a plasma glucose value \< 3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. Severe hypoglycaemia according to the ADA definition: an episode requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions.
| Episodes | Liraglutide | Placebo |
|---|---|---|
| Number of Treatment Emergent Severe or Blood Glucose Confirmed Symptomatic Hypoglycaemia Episodes | 0 | 3 |
Fasting total cholesterol measured in mg/dL. Observed mean change in fasting total cholesterol from baseline (week 0) to week 26 is presented as ratio to baseline value.
| Ratio | Liraglutide | Placebo |
|---|---|---|
| Change in Fasting Blood Lipids - Total Cholesterol | 0.95 ± 45.1 | 0.99 ± 42.3 |
Low density lipoprotein (LDL) cholesterol measured in mg/dL. Observed mean change in fasting low density lipoprotein cholesterol from baseline (week 0) to week 26 is presented as ratio to baseline value.
| Ratio | Liraglutide | Placebo |
|---|---|---|
| Change in Fasting Blood Lipids - Low Density Lipoprotein (LDL) Cholesterol | 0.97 ± 58.6 | 1.01 ± 54.1 |
High density lipoprotein (HDL) cholesterol measured in mg/dL. Observed mean change in fasting high density lipoprotein cholesterol from baseline (week 0) to week 26 is presented as ratio to baseline value.
| Ratio | Liraglutide | Placebo |
|---|---|---|
| Change in Fasting Blood Lipids - High Density Lipoprotein (HDL) Cholesterol | 1.05 ± 41.4 | 1.01 ± 39.7 |
Very low density lipoprotein (VLDL) cholesterol measured in mg/dL. Observed mean change in fasting very low density lipoprotein cholesterol from baseline (week 0) to week 26 is presented as ratio to baseline value.
| Ratio | Liraglutide | Placebo |
|---|---|---|
| Change in Fasting Blood Lipids - Very Low Density Lipoprotein (VLDL) Cholesterol | 0.83 ± 69.0 | 0.94 ± 64.5 |
Fasting triglycerides measured in mg/dL. Observed mean change in fasting triglycerides from baseline (week 0) to week 26 is presented as ratio to baseline value.
| Ratio | Liraglutide | Placebo |
|---|---|---|
| Change in Fasting Blood Lipids-triglycerides | 0.81 ± 71.5 | 0.93 ± 70.0 |
Free fatty acids measured in mg/dL. Observed mean change in fasting free fatty acids from baseline (week 0) to week 26 is presented as ratio to baseline value.
| Ratio | Liraglutide | Placebo |
|---|---|---|
| Change in Fasting Blood Lipids- Free Fatty Acids (FFA) | 0.80 ± 86.6 | 0.86 ± 92.0 |
Change from baseline (week 0) to week 26 in waist circumference ('in-trial' observation period).
| cm | Liraglutide | Placebo |
|---|---|---|
| Change in Waist Circumference | -4.28 ± 11.19 | -1.77 ± 4.42 |
Change from baseline (week 0) in systolic blood pressure after 26 weeks ('in-trial' observation period).
| mmHg | Liraglutide | Placebo |
|---|---|---|
| Change in Systolic Blood Pressure | -1.95 ± 13.42 | -3.35 ± 12.36 |
Change from baseline (week 0) in diastolic blood pressure after 26 weeks ('in-trial' observation period).
| mmHg | Liraglutide | Placebo |
|---|---|---|
| Change in Diastolic Blood Pressure | -0.72 ± 8.04 | -1.12 ± 8.55 |
Percentage of subjects who achieve HbA1c reduction above or equal to 1% (11mmol/mol) and weight loss above or equal to 3%, after 26 weeks ('in-trial' observation period).
| Percentage of participants | Liraglutide | Placebo |
|---|---|---|
| Yes | 46.43 | 41.24 |
| No | 53.57 | 58.76 |
Collected over Week 0 (randomisation visit) to week 26 (end-of-treatment visit) + 7 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Liraglutide | 0/202 (0%) | 5/202 (2.5%) | 87/202 (43.1%) |
| Placebo | 0/100 (0%) | 1/100 (1%) | 8/100 (8%) |
| Event | Liraglutide | Placebo |
|---|---|---|
| Acute kidney injuryRenal and urinary disorders | 0/202 | 1/100 |
| UreterolithiasisRenal and urinary disorders | 0/202 | 1/100 |
| Angina unstableCardiac disorders | 1/202 | 0/100 |
| Cardiac failure congestiveCardiac disorders | 1/202 | 0/100 |
| CholecystitisHepatobiliary disorders | 1/202 | 0/100 |
| Congestive cardiomyopathyCardiac disorders | 1/202 | 0/100 |
| Eyelid cystEye disorders | 1/202 | 0/100 |
| HaemorrhoidsGastrointestinal disorders | 1/202 | 0/100 |
| Lower gastrointestinal haemorrhageGastrointestinal disorders | 1/202 | 0/100 |
| Event | Liraglutide | Placebo |
|---|---|---|
| NauseaGastrointestinal disorders | 53/202 | 6/100 |
| Decreased appetiteMetabolism and nutrition disorders | 19/202 | 0/100 |
| DiarrhoeaGastrointestinal disorders | 19/202 | 3/100 |
| ConstipationGastrointestinal disorders | 18/202 | 0/100 |
| VomitingGastrointestinal disorders | 17/202 | 2/100 |
Full analysis set (FAS) includes all randomised subjects. Subjects in the FAS contribute to the evaluation 'as randomised'.
| Age, Continuous(Years) | Liraglutide | Placebo | Total |
|---|---|---|---|
| Mean | 54.72 ± 10.08 | 56.03 ± 9.89 | 55.15 ± 10.02 |
| Sex: Female, Male(Participants) | Liraglutide | Placebo | Total |
|---|---|---|---|
| Female | 78 | 42 | 120 |
| Male | 125 | 58 | 183 |
| Ethnicity (NIH/OMB)(Participants) | Liraglutide | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 59 | 35 | 94 |
| Not Hispanic or Latino | 144 | 65 | 209 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Liraglutide | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 |
| Asian | 38 | 15 | 53 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| Black or African American | 12 | 5 | 17 |
| White | 131 | 59 | 190 |
| Other | 21 | 20 | 41 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Ran from Mar 2017 to primary completion in May 2018, 14 months.
Results were first posted in Jul 2019, 1 year 2 months after primary completion.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 14 months is below that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Liraglutide